Trial Profile
Phase II study of Carboplatin and alternate-day administrations of TS-1 in patients with advanced squamous cell lung cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2017
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 05 Mar 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 22 Jan 2013 New trial record